Vitrolife’s CEO Bronwyn Brophy came across as executive and resourceful during her first CMD at Vitrolife. The new 5-year target is >10% organic growth target is perhaps the most interesting. Our take is that Vitrolife has established a sufficient footprint where future opportunities are more related to regional commercial opportunities, innovation combined with complementary acquisitions supporting the vertical integration strategy. Our updated view is a base case valuation of SEK 235 (220) and a Bull Case of SEK 375 (330), and a Bear Case of SEK 95 (95).

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

Vitrolife - Industrious and purposeful consolidation

© Modular Finance, source Nordic Press Releases